Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of CTI BioPharma Corp (NASDAQ: CTIC) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of CTI BioPharma Corp (NASDAQ: CTIC) concerning whether a series of statements by CTI BioPharma Corp regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On February 8, 2016, CTI BioPharma Corp announced that it had been notified by the U.S. Food and Drug Administration (FDA) that the FDA had placed a partial hold on clinical studies of CTI's main product, pacritinib. The U.S. Food and Drug Administration has recommended that CTI BioPharma Corp adjust its protocols for randomized studies to disallow crossover to pacritinib, provide certain notifications, revise certain statements in the investigator's brochure and informed consent documents and other actions.

On this news, NASDAQ: CTIC shares dropped nearly 60% during pre-market trading on February 8, 2016.

Based in Seattle, Washington, and founded in 1991 CTI BioPharma Corp is a biopharmaceutical company, engaged in the development and commercialization of certain therapies for blood-related cancers.

If you purchased shares of CTI BioPharma Corp (NASDAQ: CTIC) on or before February 8, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185